×

Tonghua Dongbao's Insulin Aspart, as part of basal-bolus therapy, approved for sale in China

Date：2021-10-21
Author：東寶
Views：3

Tonghua Dongbao's Insulin Aspart Injection (tradename: Ruisulin) was approved for sale in China the other day, adding another member to the Company's insulin analog family since the launch of Insulin Glargine in 2019. This basal-bolus insulin therapy will enrich the choices for patients with diabetes, and sharpen the Company's competitive edge and consolidate its lead in the field of diabetes treatment in China.

0

821--------m.guoyikj.cn

164--------m.guxo.com.cn

559--------m.n7tb2.cn

395--------m.ogmk.cn

673--------m.huayuqb.cn

907--------m.rzrdy.cn

631--------m.bg4s4.cn

968--------m.zhu7jie.cn

217--------m.zy16888.com.cn

415--------m.katze.cn